Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying users area

Try for free

Allergan PLC pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan PLC, consolidated cash flow statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income (loss)
Depreciation
Amortization
Provision for inventory reserve
Share-based compensation
Deferred income tax benefit
Pre-tax gain on sale of businesses to Teva
Non-cash tax effect of gain on sale of businesses to Teva
Goodwill impairments
In-process research and development impairments
Loss on asset sales and impairments, net
Net income impact of other-than-temporary loss on investment in Teva securities
Charge to settle Teva related matters
Loss on forward sale of Teva shares
Gain on sale of Teva securities, net
Amortization of inventory step-up
Gain on sale of businesses
Non-cash extinguishment of debt
Cash discount related to extinguishment of debt
Amortization of deferred financing costs
Amortization of right of use assets
Contingent consideration adjustments, including accretion
Excess tax benefit from stock-based compensation
Other, net
(Increase) decrease in accounts receivable, net
(Increase) decrease in inventories
(Increase) decrease in prepaid expenses and other current assets
Increase (decrease) in accounts payable and accrued expenses
Increase (decrease) in income and other taxes payable
Increase (decrease) in other assets and liabilities
Changes in assets and liabilities, net of effects of acquisitions
Reconciliation to net cash provided by operating activities
Net cash provided by operating activities
Additions to property, plant and equipment
Additions to product rights and other intangibles
Sale of businesses to Teva
Additions to investments
Proceeds from sale of investments and other assets
Payments to settle Teva related matters
Proceeds from sales of property, plant and equipment
Acquisitions of businesses, net of cash acquired
Net cash (used in) provided by investing activities
Proceeds from borrowings of long-term indebtedness, including credit facility
Payments on debt, including capital lease obligations and credit facility
Debt issuance and other financing costs
Proceeds from issuance of preferred shares
Proceeds from issuance of ordinary shares
Payments of contingent consideration and other financing
Proceeds from stock plans
Proceeds from forward sale of Teva securities
Payments to settle Teva related matters
Repurchase of ordinary shares
Dividends paid
Excess tax benefit from stock-based compensation
Net cash provided by (used in) financing activities
Effect of currency exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Allergan PLC net cash provided by operating activities decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Allergan PLC net cash (used in) provided by investing activities increased from 2017 to 2018 but then decreased significantly from 2018 to 2019.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Allergan PLC net cash provided by (used in) financing activities decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.